ArticleJournal of molecular modeling2026
Predicting enantiomer migration order of levobunolol via sequential computational modeling.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextA detailed molecular-level rationale for the enantioseparation of the β-blocker levobunolol (BUN) by substituted β-cyclodextrins (β-CDs) is presented through high-level computational modeling. The calculations consistently reveal that the therapeutically active (+)-[S]-BUN enantiomer forms more stable inclusion complexes than the (-)-[R]-enantiomer with both carboxymethyl-β-CD (CM-β-CD) and sulfated-β-CD (SF-β-CD) selectors. Non-covalent interaction (NCI) reveals that the superior stability of the S-enantiomer arises from a more continuous dispersive interaction envelope and a more compact network of electrostatic and hydrogen bonds. For the most effective selector, SF-β-CD, the complexation Gibbs free energy (ΔG) in an aqueous medium is -29.5 kcal/mol for (+)-[S]-BUN versus -17.1 kcal/mol for (-)-[R]-BUN. This results in a large free energy difference (ΔΔG) of 12.4 kcal/mol, indicating exceptional enantioselectivity. The NCI isosurfaces also confirm that the S-isomer achieves optimal stereoelectronic complementarity with the host's sulfate and hydroxyl groups, showing lower steric penalties than the R-isomer. These findings provide a robust prediction of a longer electrophoretic migration time for the (+)-[S]-enantiomer and validate SF-β-CD as a highly efficient chiral selector for BUN, underscoring the power of in silico methods to elucidate complex chiral recognition mechanisms.
methodsSemiempirical geometry, frequency, non-covalent, 2nd version, eXtended Tight Binding (GFN2-xTB) and Density Functional Theory (DFT) (ωB97X-D3/6-31G(d,p) and ωB97X-D3/6-311 + G(d,p)) methods were employed in both gas and aqueous phases. NCI analysis was also performed. All DFT and semiempirical calculations were carried out using the ORCA 5.0 software package. The NCI analysis was carried out using the Multiwfn program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.